M. Rabin

P. Jänne, H. Hatabu, D. Jackman, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival.

H. Hatabu, D. Jackman, M. Nishino, 2015, European journal of radiology.

Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib

B. Yeap, D. Costa, D. Jackman, 2010, Clinical Cancer Research.

First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions.

J. Niland, J. Vandergrift, D. Ettinger, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer

T. Lynch, S. Kesari, D. Jackman, 2015, Oncotarget.

High Sensitivity of Plasma Cell-Free DNA Genotyping in Cases With Evidence of Adequate Tumor Content

C. Paweletz, M. Rabin, G. Oxnard, 2021, JCO precision oncology.

Case report of tracheobronchial squamous cell carcinoma treated with radiation therapy and concurrent chemotherapy

R. Mak, M. Rabin, J. P. Marcoux, 2016, Advances in radiation oncology.

Unresectable adenoid cystic carcinoma of the trachea treated with chemoradiation.

J. Reilly, A. Allen, M. Rabin, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Volumetric tumor growth in advanced non‐small cell lung cancer patients with EGFR mutations during EGFR‐tyrosine kinase inhibitor therapy

P. Jänne, H. Hatabu, D. Jackman, 2013, Cancer.

RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.

P. Jänne, H. Hatabu, D. Jackman, 2013, AJR. American journal of roentgenology.

Functional characterization of Wilms tumor-suppressor WTX and tumor-associated mutants

J. Licht, M. Rabin, D. Min, 2011, Oncogene.

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

C. Paweletz, A. Redig, P. Jänne, 2018, JAMA oncology.

Clinical decision support for symptom management in lung cancer patients: A group RCT.

D. Lobach, R. McCorkle, M. Cooley, 2021, Journal of pain and symptom management.

Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer.

D. Jackman, M. Rabin, J. Jacobson, 2017, Journal of oncology practice.

Cost and survival analysis before and after implementation of Dana-Farber Clinical Pathways for Patients with Stage IV Non-Small Cell Lung Cancer.

D. Jackman, M. Rabin, J. Jacobson, 2017 .

Percutaneous CT-guided radiofrequency ablation of symptomatic bilateral adrenal metastases in a single session.

S. Silverman, K. Tuncali, P. Morrison, 2006, Journal of vascular and interventional radiology : JVIR.

Rates of central nervous system progression in non-small cell lung cancer patients treated with EGFR-TKI's vs. chemotherapy

B. Yeap, D. Jackman, M. Rabin, 2008 .

Quality of Care for Older Patients With Cancer in the Veterans Health Administration Versus the Private Sector

B. McNeil, E. Lamont, C. Earle, 2011, Annals of Internal Medicine.

Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome

H. Hatabu, M. Nishino, M. Rabin, 2019, European journal of radiology open.

Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery

P. Jänne, D. Sugarbaker, R. Bueno, 2009, Cancer.

Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare.

B. McNeil, E. Lamont, C. Earle, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Aggressive end-of-life (EOL) chemotherapy (CT) use in metastatic non-small cell lung cancer (mNSCLC): A National Comprehensive Cancer Network (NCCN) outcomes database analysis.

J. Niland, D. Ettinger, G. Otterson, 2011, Journal of Clinical Oncology.

Point-of-care clinical decision support for cancer symptom management: Results of a group randomized trial.

P. Catalano, D. Lobach, R. McCorkle, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Algorithm-based decision support for symptom self-management among adults with Cancer: results of usability testing

David F. Lobach, Donna L. Berry, Manan Nayak, 2018, BMC Medical Informatics and Decision Making.

Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in BRD4-NUTM1 NUT Carcinoma Harboring a BRD4 Splice Site Mutation.

P. Jänne, L. Chirieac, J. LoPiccolo, 2023, JCO precision oncology.

Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer

P. Jänne, D. Costa, N. Wagle, 2020, Clinical Cancer Research.

Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab

H. Hatabu, Sarah K. Cryer, D. Jackman, 2012, Cancer imaging : the official publication of the International Cancer Imaging Society.

Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer

T. Kolevska, L. Sequist, P. Fidias, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of erlotinib in chemo-naive women with advanced pulmonary adenocarcinoma

P. Jänne, N. Lindeman, D. Jackman, 2007 .

Phase II study of the EGFR tyrosine kinase erlotinib in patients ≥ 70 years of age with previously untreated advanced non-small cell lung carcinoma

P. Jänne, J. Temel, T. Lynch, 2005 .

P. Jänne, J. Temel, T. Lynch, 2004 .

Clinician perspectives on symptom and quality of life experiences of patients during cancer therapies: Implications for eHealth

Donna L Berry, Ilana Braun, Mary E Cooley, 2017, Psycho-oncology.

A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer

T. Lynch, S. Kesari, D. Jackman, 2015, Oncotarget.

Safety of image guided research biopsies in patients with thoracic malignancies.

P. Jänne, D. Glazer, M. Rabin, 2022, Lung cancer.

NSCLC Treated at NCCN Institutions With NCCN Guidelines for Patients Diagnosed With Metastatic First-Line Systemic Therapy Practice Patterns and Concordance

J. Niland, J. Vandergrift, G. Otterson, 2012 .

Pembrolizumab-Associated Expansion of Radiation-Induced Morphea Responsive to Dupilumab: A Case Report.

N. LeBoeuf, M. Rabin, C. Larocca, 2023, Clincal and Experimental Dermatology.

Osimertinib-Induced Cutaneous Vasculitis Responsive to Low-Dose Dapsone Without Interruption of Anticancer Therapy: A Case Report and Review of the Literature

N. LeBoeuf, M. Rabin, J. H. Young, 2022, JTO Clinical and Research Reports.

Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival.

H. Hatabu, D. Jackman, M. Nishino, 2015, European journal of radiology.